The Vam6 antibody targets the Vam6/Vps39 protein, a conserved component of the HOPS complex (Homotypic fusion and Protein Sorting) and vCLAMP (vacuole and mitochondria patch) structures. These complexes mediate organelle fusion, nutrient transport, and stress responses in eukaryotic cells .
Key attributes of Vam6 antibodies include:
Reactivity: Broad cross-species recognition, including Saccharomyces cerevisiae, Candida albicans, Cryptococcus neoformans, and mammalian systems .
Immunogen: Typically derived from a synthetic peptide or recombinant protein fragment (e.g., residues 710–760 in human VPS39) .
Applications: Western blot (WB), ELISA, immunofluorescence, and co-immunoprecipitation (Co-IP) .
Vam6 is critical for virulence in fungal pathogens:
In Candida albicans, Vam6 deficiency leads to mitochondrial swelling, reduced antioxidant enzyme activity, and impaired hyphal development under oxidative stress .
Cryptococcus neoformans mutants lacking Vam6 exhibit defective polyphosphate metabolism, mitochondrial dysfunction, and attenuated virulence .
Vam6 facilitates vCLAMP formation, which regulates:
Phospholipid trafficking between mitochondria and vacuoles .
Polyphosphate (polyP) synthesis and oxidative stress responses .
In tumor immunology, Vam6 modulates iNKT cell function:
Increased Vam6 expression suppresses mTORC1 activation and IFN-γ production via Rab7a-Vam6-AMPK complex formation .
Targeting Vam6 enhances anti-tumor efficacy by restoring iNKT cell activity .
KEGG: spo:SPAC23H4.14
STRING: 4896.SPAC23H4.14.1
Vam6/Vps39 is a multifunctional protein that serves critical roles in various cellular processes. It functions as a component of both the homotypic fusion and vacuole protein sorting (HOPS) complex and vacuole and mitochondria patch (vCLAMP) membrane contact sites. Research has demonstrated that Vam6 is essential for:
Vacuolar morphology maintenance and function
Mitochondrial health and resistance to oxidative stress
Endomembrane trafficking
Polyphosphate (polyP) metabolism
TORC1 pathway regulation in response to amino acids
In fungal pathogens like Candida albicans and Cryptococcus neoformans, Vam6 plays crucial roles in virulence and stress responses . In mammalian systems, Vam6 has been implicated in immune cell function through modulation of AMPK-mTORC1 signaling pathways .
Vam6/Vps39 antibodies have been validated for multiple experimental applications:
| Application | Typical Working Dilution | Common Sample Types |
|---|---|---|
| Western Blot | 0.5-1 μg/mL | Cell/tissue lysates |
| Immunohistochemistry | 5-20 μg/mL | Paraffin-embedded tissues |
| Immunofluorescence | 5-20 μg/mL | Fixed cells, tissue sections |
| ELISA | Varies by antibody | Purified protein, cell lysates |
| Co-immunoprecipitation | Varies by experiment | Cell lysates |
When selecting antibodies, researchers should consider specificity across isoforms, as at least four isoforms of Vps39 are known to exist in mammals . Validation across multiple applications is recommended to ensure reliability in your specific experimental system.
Vam6 has been reported to localize to multiple cellular compartments, primarily vacuolar membranes and mitochondria-vacuole contact sites (vCLAMPs). A comprehensive validation approach should include:
Co-localization studies: Use established organelle markers alongside Vam6 antibodies:
Vacuolar membrane: FM4-64 or LAMP2
Mitochondria: MitoTracker Red or Tom20
Late endosomes: Rab7a
Multiple imaging techniques:
Functional verification: In C. albicans, researchers labeled mitochondria with Csp37-GFP (outer mitochondrial membrane) alongside vacuole markers to confirm Vam6's role in vCLAMP formation .
Critically, Vam6 localization can be influenced by nutritional status and stress conditions. For example, in S. pombe, Vam6-Gtr1 interaction was only detectable in cells grown with amino acids, not during nitrogen starvation, despite co-localization under both conditions .
Vam6/Vps39 shows varying degrees of conservation across species, affecting antibody selection and experimental design:
| Species | Key Considerations | Validated Applications |
|---|---|---|
| Human | Multiple isoforms exist; antibody may detect all four | WB, IF, IHC-P, ELISA |
| Mouse | Often used in knockout/heterozygous models | WB, IF, IHC-P |
| Rat | Limited validation in some antibody products | WB, sometimes IF |
| S. cerevisiae | Called Vam6; differs from mammalian homologs | WB, ELISA |
| C. albicans | Homolog of S. cerevisiae Vps39 | Genetic studies primarily |
| C. neoformans | Called Vam6/Vps39/TRAP1-domain protein | Genetic studies primarily |
When working with fungal systems, researchers have often relied on epitope tagging (GFP, mCherry) rather than antibodies against the native protein . For cross-species studies, western blotting with appropriate controls should be performed to confirm antibody specificity.
Distinguishing between Vam6's functions in different protein complexes requires careful experimental design:
Domain-specific approaches:
Co-immunoprecipitation strategy:
Phenotypic analysis:
In C. neoformans, researchers investigating these dual roles used a comprehensive approach combining morphological studies, organelle-specific staining, and metabolic phenotyping to distinguish HOPS vs. vCLAMP functions of Vam6 .
Investigating Vam6's function in oxidative stress response requires multi-parameter analysis:
ROS measurement techniques:
Flow cytometry with ROS-sensitive dyes (DCFDA)
Plate-based fluorometric assays for high-throughput screening
Mitochondrial superoxide indicators for organelle-specific ROS
Mitochondrial function assessment:
Antioxidant enzyme profiling:
Measure SOD1 activity in wild-type vs. vam6 mutants
Quantify glutathione levels and recycling
In C. albicans, researchers found that vam6Δ/Δ mutants showed increased sensitivity to H₂O₂, with reduced antioxidant enzyme activity and elevated ROS levels. Similarly, in C. neoformans, deletion of Vam6 resulted in increased ROS accumulation when cells were treated with hemin .
Successful co-immunoprecipitation of Vam6 and its interaction partners requires careful optimization:
Lysis buffer selection:
Antibody-bead preparation:
Pre-incubate antibodies with Dynabeads protein G at 4°C for at least 30 minutes
Use 1-5 μg of antibody per sample
Include appropriate isotype controls (e.g., rabbit IgG)
Incubation conditions:
Overnight incubation at 4°C improves yield
Gentle rotation to maintain bead suspension without damaging complexes
Known technical challenges:
For protein complexes at membrane contact sites, such as vCLAMPs, crosslinking prior to lysis may help preserve transient interactions between organelles.
Researchers have reported variations in the observed molecular weight of Vam6/Vps39:
| Source | Calculated MW | Observed MW | Possible Explanation |
|---|---|---|---|
| Human VPS39 | 101.8 kDa | 68 kDa | Post-translational modifications, isoforms |
| Yeast Vam6 | Varies by species | Multiple bands | Degradation products, splice variants |
To address these discrepancies:
Sample preparation optimization:
Include fresh protease inhibitors
Avoid repeated freeze-thaw cycles
Consider gentler lysis methods for membrane proteins
Control experiments:
Include positive controls from validated sources
Use blocking peptides to confirm specificity
Compare wild-type and knockout/knockdown samples
Antibody validation:
Test multiple antibodies targeting different epitopes
Verify with tagged constructs (GFP/mCherry-Vam6) using tag-specific antibodies
If multiple bands are observed, phosphatase treatment can help determine if post-translational modifications contribute to the molecular weight variation.
Recent studies highlight Vam6's potential as a therapeutic target for fungal infections:
Virulence connection:
Potential intervention strategies:
Target vCLAMP formation to disrupt fungal stress responses
Inhibit Vam6-dependent iron acquisition pathways
Disrupt vacuolar function essential for fungal survival under host conditions
Therapeutic considerations:
Structural differences between fungal and mammalian Vam6 could enable selective targeting
Combination approaches targeting both Vam6 and other stress response pathways may increase efficacy
The World Health Organization recently ranked C. neoformans in the critical priority group for public health importance, highlighting the need for novel antifungal strategies .
Advanced methodologies are expanding our understanding of Vam6 biology:
Live-cell imaging approaches:
Photo-switchable fluorescent proteins to track Vam6 movement between compartments
FRET-based sensors to detect protein-protein interactions in real-time
Lattice light-sheet microscopy for improved spatiotemporal resolution
Proximity labeling techniques:
BioID or APEX2 fusions to identify proteins in close proximity to Vam6
Helps identify transient interaction partners at membrane contact sites
CRISPR-based technologies:
Functional sensors:
These advanced techniques provide unprecedented insights into the dynamic roles of Vam6 in various cellular processes and disease states.